Parkinson's Disease Neuroprotection Clinical Trial
帕金森病神经保护临床试验
基本信息
- 批准号:7555183
- 负责人:
- 金额:$ 9.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-15 至 2012-11-30
- 项目状态:已结题
- 来源:
- 关键词:AchievementAllyAlzheimer&aposs DiseaseAnimal ModelAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAwardBotoxCaliforniaCaringClimateClinicClinicalClinical ResearchClinical ServicesClinical TrialsCollaborationsCommunity OutreachDentistryDiagnosisDiagnosticDiscipline of NursingDiseaseDopamineDystoniaEducationEducational process of instructingFamilyFoundationsFundingGeneral HospitalsGeneticGoalsGrantHeadHealthHealth SciencesHealth ServicesHumanHuman ResourcesHyperactive behaviorImmunologicsIndustryInflammatoryInternationalMediatingMedicalMedical StaffMedical centerMedicineMemory DisordersMicrogliaMissionMovement DisordersNeurodegenerative DisordersNeurologic DysfunctionsNeurologyNeuroprotective AgentsNeurosciencesNumbersPainPain ClinicsParkinson DiseaseParkinsonian DisordersPathogenesisPatient CarePatientsPharmaceutical PreparationsPharmacy facilityPhysiciansPopulationProcessProtocol AgentRecording of previous eventsResearchResearch PersonnelResearch TrainingSan FranciscoSchoolsScientistSclerosisServicesSocial SciencesSourceSpecific qualifier valueStudentsTestingTrainingTraining and EducationUnited StatesUnited States National Institutes of HealthUniversitiesVeteransbasecytokinedopaminergic neuronexperiencemedical schoolsmedical specialtiesmemberneuroprotectionnovelprospectiveresponsetertiary caretreatment trialuptake
项目摘要
DESCRIPTION (provided by applicant): Parkinson's disease (PD) is the second most common neurodegenerative disorder. While a number symptomatic therapies have been developed, no treatment has been identified that halts or slows this progressive disorder. For a number of reasons, we believe that it is appropriate to begin a prospective clinical trial of one or more of the more promising agents to determine whether they offer benefit. The aim of this application is to participate as a clinical center in a collaborative study of neuroprotective agents. The agents and protocol will be specified by NINDS.
UCSF has a long history in providing subspecialty care for subjects with PD. The UCSF Parkinson's Disease Clinic & Research Center (PDCRQ has been involved in a number of clinical trials to elucidate the neurologic dysfunction underlying PD as well as testing a variety of novel treatments for PD. This research has included a number of industry sponsored treatment trials for subjects with early to advanced PD. A large diverse, local population provides a reliable source of motivated subjects for clinical research. The experience of the UCSF PDCRC in evaluating, selecting and following subjects with PD make it an ideal candidate for a multicenter, prospective trial of a potential neuroprotectant therapy.
The ideal neuroprotective treatment should be effective, inexpensive, well tolerated, safe, easy to administer, and have few interactions with common medications. A number of studies over the last decade 'in humans and experimental animals have demonstrated a local immunologic response mediated by microglia and a number of inflammatory cytokines. Moreover, several animal models of PD have demonstrated that anti-inflammatory medications can interfere with the local immunologic response, and that they may preserve function of dopaminergic neurons. Although emerging understanding of the pathogenesis of PD may provide an alternative candidate for a neuroprotectant therapy, we propose that an anti-inflammatory medication would be a rational and practical candidate for the Parkinson's disease Neuroprotection Trial.
描述(由申请人提供):帕金森病(PD)是第二常见的神经退行性疾病。虽然已经开发了一些对症治疗,但尚未确定停止或减缓这种进行性疾病的治疗。出于多种原因,我们认为开始对一种或多种更有前途的药物进行前瞻性临床试验以确定它们是否提供益处是合适的。本申请的目的是作为临床中心参与神经保护剂的合作研究。药物和方案将由NINDS规定。
UCSF在为PD受试者提供专科护理方面有着悠久的历史。UCSF帕金森病诊所和研究中心(PDCRQ)参与了许多临床试验,以阐明帕金森病的神经功能障碍,并测试各种新的治疗方法。本研究包括许多行业申办的针对早期至晚期PD受试者的治疗试验。一个大的多样性,当地人口提供了一个可靠的来源,积极的受试者的临床研究。UCSF PDCRC在评估、选择和随访PD受试者方面的经验使其成为潜在神经保护剂治疗的多中心、前瞻性试验的理想候选者。
理想的神经保护治疗应该是有效的,廉价的,耐受性好,安全,易于管理,并与常见药物的相互作用很少。在过去的十年中,在人类和实验动物中的许多研究已经证明了由小胶质细胞和许多炎性细胞因子介导的局部免疫应答。此外,几种PD动物模型已经证明抗炎药物可以干扰局部免疫反应,并且它们可以保护多巴胺能神经元的功能。虽然对PD发病机制的新认识可能为神经保护剂治疗提供了另一种候选药物,但我们建议抗炎药物将是帕金森病神经保护试验的合理和实用的候选药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL Jeffrey AMINOFF其他文献
MICHAEL Jeffrey AMINOFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL Jeffrey AMINOFF', 18)}}的其他基金
A MULTICENTER, DOUBLE-BLIND, PILOT STUDY OF COQ10 AND GPI 1485 IN SUBJECTS WITH)
COQ10 和 GPI 1485 的多中心、双盲试点研究
- 批准号:
7202675 - 财政年份:2005
- 资助金额:
$ 9.57万 - 项目类别:
MINOCYCLINE AND CREATINE IN SUBJECTS WITH EARLY UNTREATED PARKINSON'S DISEASE
米诺环素和肌酸在早期未经治疗的帕金森病患者中的应用
- 批准号:
7202655 - 财政年份:2005
- 资助金额:
$ 9.57万 - 项目类别:
Parkinson's Research: The Organized Genetics Initiative (PROGENI)
帕金森氏症研究:组织遗传学计划 (PROGENI)
- 批准号:
6972241 - 财政年份:2004
- 资助金额:
$ 9.57万 - 项目类别:
Minocycline and Creatine in Subjects With Early Untreated Parkinson's Disease
米诺环素和肌酸治疗早期未经治疗的帕金森病患者
- 批准号:
6972315 - 财政年份:2004
- 资助金额:
$ 9.57万 - 项目类别:
Parkinson's Disease Neuroprotection Clinical Trial
帕金森病神经保护临床试验
- 批准号:
6545839 - 财政年份:2002
- 资助金额:
$ 9.57万 - 项目类别:
Parkinson's Disease Neuroprotection Clinical Trial
帕金森病神经保护临床试验
- 批准号:
7012766 - 财政年份:2002
- 资助金额:
$ 9.57万 - 项目类别:
Parkinson's Disease Neuroprotection Clinical Trial
帕金森病神经保护临床试验
- 批准号:
8204822 - 财政年份:2002
- 资助金额:
$ 9.57万 - 项目类别:
Parkinson's Disease Neuroprotection Clinical Trial
帕金森病神经保护临床试验
- 批准号:
8601321 - 财政年份:2002
- 资助金额:
$ 9.57万 - 项目类别:
Parkinson's Disease Neuroprotection Clinical Trial
帕金森病神经保护临床试验
- 批准号:
6659085 - 财政年份:2002
- 资助金额:
$ 9.57万 - 项目类别:
Parkinson's Disease Neuroprotection Clinical Trial
帕金森病神经保护临床试验
- 批准号:
8033229 - 财政年份:2002
- 资助金额:
$ 9.57万 - 项目类别:
相似海外基金
台湾の小中学校におけるジェンダー平等教育の実践-教員が「ally」となるためにはー
台湾中小学性别平等教育实践——让教师成为“盟友”
- 批准号:
24K05716 - 财政年份:2024
- 资助金额:
$ 9.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allostatic Load in Latino Youth (ALLY) study: The Role of Discrimination and Environmental Racism
拉丁裔青年的均衡负荷 (ALLY) 研究:歧视和环境种族主义的作用
- 批准号:
10677710 - 财政年份:2022
- 资助金额:
$ 9.57万 - 项目类别:
Turning an enemy into an ally: Privacy In Machine Learning (Pri-ML)
化敌为友:机器学习中的隐私 (Pri-ML)
- 批准号:
DGECR-2022-00376 - 财政年份:2022
- 资助金额:
$ 9.57万 - 项目类别:
Discovery Launch Supplement
Turning an enemy into an ally: Privacy In Machine Learning (Pri-ML)
化敌为友:机器学习中的隐私 (Pri-ML)
- 批准号:
RGPIN-2022-03721 - 财政年份:2022
- 资助金额:
$ 9.57万 - 项目类别:
Discovery Grants Program - Individual
Animals, Lifeways and Lifeworlds in Yup'ik Archaeology (ALLY): Subsistence, Technologies, and Communities of Change
尤皮克考古学中的动物、生活方式和生命世界(ALLY):生存、技术和变革社区
- 批准号:
AH/N504543/1 - 财政年份:2016
- 资助金额:
$ 9.57万 - 项目类别:
Research Grant
Marie Duval presents Ally Sloper: the female cartoonist and popular theatre in London 1869-85.
玛丽·杜瓦尔 (Marie Duval) 介绍艾丽·斯洛珀 (Ally Sloper):1869-85 年伦敦的女漫画家和受欢迎的剧院。
- 批准号:
AH/M000257/1 - 财政年份:2014
- 资助金额:
$ 9.57万 - 项目类别:
Research Grant
Development of new function by suppression of martensitic transition in Fe-Pt ally
通过抑制 Fe-Pt 合金中的马氏体转变开发新功能
- 批准号:
21860009 - 财政年份:2009
- 资助金额:
$ 9.57万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Studies on the biocompatibility of magnesium ally implant materials
镁合金植入材料的生物相容性研究
- 批准号:
366590-2008 - 财政年份:2008
- 资助金额:
$ 9.57万 - 项目类别:
University Undergraduate Student Research Awards
High strength and high conductivity nanoparticle-precipitated copper ally : optimizaiton of thermomechanical processing
高强度和高导电性纳米颗粒沉淀铜合金:热机械加工的优化
- 批准号:
15560601 - 财政年份:2003
- 资助金额:
$ 9.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Fabrication of Integrated Air Valve Chip Using Shape Memory Ally Thin Film
使用形状记忆合金薄膜制造集成气阀芯片
- 批准号:
06555072 - 财政年份:1994
- 资助金额:
$ 9.57万 - 项目类别:
Grant-in-Aid for Scientific Research (A)